About Cardiovascular Systems (NASDAQ:CSII)
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:CSII
- CUSIP: 14161910
- Web: www.csi360.com
Capitalization:- Market Cap: $877.75 million
- Outstanding Shares: 32,991,000
Average Prices:- 50 Day Moving Avg: $28.64
- 200 Day Moving Avg: $30.19
- 52 Week Range: $21.29 - $33.11
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 146.33
- P/E Growth: 177.27
Sales & Book Value:- Annual Revenue: $204.91 million
- Price / Sales: 4.24
- Book Value: $3.60 per share
- Price / Book: 7.32
Profitability:- EBITDA: $5.43 million
- Net Margins: -0.87%
- Return on Equity: 0.88%
- Return on Assets: 0.58%
Debt:- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 3.88%
- Quick Ratio: 3.47%
Misc:- Average Volume: 222,566 shs.
- Beta: 2.54
- Short Ratio: 4.87
Frequently Asked Questions for Cardiovascular Systems (NASDAQ:CSII)
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems, Inc. (NASDAQ:CSII) announced its earnings results on Wednesday, August, 2nd. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.07. The business earned $52.90 million during the quarter, compared to analysts' expectations of $51.98 million. Cardiovascular Systems had a positive return on equity of 0.88% and a negative net margin of 0.87%. The business's revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.15) earnings per share. View Cardiovascular Systems' Earnings History.
When will Cardiovascular Systems make its next earnings announcement?
Where is Cardiovascular Systems' stock going? Where will Cardiovascular Systems' stock price be in 2017?
7 brokers have issued 1-year target prices for Cardiovascular Systems' shares. Their predictions range from $30.00 to $40.00. On average, they expect Cardiovascular Systems' stock price to reach $34.25 in the next twelve months. View Analyst Ratings for Cardiovascular Systems.
What are analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Cardiovascular Systems has already commenced the process of seeking approval for commercial sales in both Europe and Japan. In the event that the company fails to successfully enter international markets and manage business on a global scale, it might negatively affect Cardiovascular Systems’ financial results. Also, the company witnessed a net loss in the last reported quarter. Moreover, stiff competition adds to the woes. On a positive note, over the past year, Cardiovascular Systems has been trading above the broader industry. Cardiovascular Systems delivered remarkable fourth-quarter 2017 results. Moreover, the improvement in margins is encouraging. Overall, the company’s’ fiscal 2017 performance has been impressive. The company’s fiscal 2018 guidance also instils confidence in investors. It received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device." (10/10/2017)
- 2. Needham & Company LLC analysts commented, "We are reiterating our Buy rating on CSII, raising our FY18 and FY19 estimates, and raising our price target to $37 from $32. Over the next few quarters, we expect revenue growth to slow due to tougher comps but we expect earnings upside to drive shares higher. We expect the ECLIPSE trial and Japan to drive strong coronary growth in coming years." (7/14/2017)
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), Intersect ENT (XENT), K2M Group Holdings (KTWO), AtriCure (ATRC), CryoLife (CRY), Landauer (LDR), Meridian Bioscience (VIVO), Consort Medical plc (CSRT), Transenterix (TRXC), Transenterix (TRXC), STAAR Surgical Company (STAA), Invacare Corporation (IVC), Exactech (EXAC) and Antares Pharma (ATRS).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Scott R. Ward, Chairman of the Board, President, Chief Executive Officer
- Laurence L. Betterley, Chief Financial Officer
- Kevin J. Kenny, Chief Operating Officer
- Sandra Sedo, Chief Compliance Officer
- Alexander Rosenstein, General Counsel and Corporate Secretary
- Martha Goldberg Aronson, Independent Director
- Scott A. Bartos, Independent Director
- Brent G. Blackey, Independent Director
- Edward M. Brown, Independent Director
- William E. Cohn M.D., Independent Director
How do I buy Cardiovascular Systems stock?
Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of Cardiovascular Systems stock can currently be purchased for approximately $26.34.
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cardiovascular Systems (NASDAQ:CSII) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 3 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.57) |
| Consensus Price Target: | $34.25 (30.03% upside) |
Consensus Price Target History for Cardiovascular Systems (NASDAQ:CSII)
Analysts' Ratings History for Cardiovascular Systems (NASDAQ:CSII)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/12/2017 | Needham & Company LLC | Reiterated Rating | Buy | $37.00 | N/A |  |
| 9/22/2017 | Raymond James Financial, Inc. | Initiated Coverage | Mkt Perform -> Market Perform | | Low | |
| 9/21/2017 | Citigroup Inc. | Initiated Coverage | Market Perform | | Low | |
| 6/21/2017 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | Low | |
| 1/30/2017 | Lake Street Capital | Initiated Coverage | Buy | $40.00 | N/A | |
| 11/15/2016 | Leerink Swann | Reiterated Rating | Outperform | $30.00 | N/A | |
| 10/27/2016 | Feltl & Co. | Upgrade | Buy -> Strong-Buy | $30.00 | N/A | |
| 10/7/2016 | JMP Securities | Initiated Coverage | Outperform | $35.00 | N/A | |
| 12/23/2015 | Northcoast Research | Initiated Coverage | Buy | $18.00 | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for Cardiovascular Systems (NASDAQ:CSII)Earnings History by Quarter for Cardiovascular Systems (NASDAQ CSII)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | | | | | | N/A | |
| 8/2/2017 | Q4 2017 | ($0.05) | $0.02 | $51.98 million | $52.90 million | View | Listen | |
| 5/3/2017 | Q3 2017 | ($0.05) | ($0.05) | $51.13 million | $52.10 million | View | Listen | |
| 1/25/2017 | Q217 | ($0.06) | $0.03 | $49.72 million | $50.00 million | View | N/A | |
| 10/26/2016 | Q117 | ($0.18) | ($0.06) | $205.50 million | $49.80 million | View | Listen | |
| 8/3/2016 | Q416 | ($0.20) | ($0.15) | $46.01 million | $48.50 million | View | N/A | |
| 5/4/2016 | Q316 | ($0.54) | ($0.31) | $42.13 million | $44.50 million | View | N/A | |
| 1/21/2016 | Q216 | ($0.50) | ($0.47) | $44.82 million | $41.40 million | View | Listen | |
| 11/4/2015 | Q116 | ($0.42) | ($0.41) | $43.90 million | $43.90 million | View | N/A | |
| 8/5/2015 | Q415 | ($0.30) | ($0.27) | $50.10 million | $48.50 million | View | N/A | |
| 4/29/2015 | Q315 | ($0.33) | ($0.34) | $46.84 million | $47.00 million | View | Listen | |
| 1/28/2015 | Q215 | ($0.34) | ($0.17) | $43.97 million | $44.70 million | View | Listen | |
| 10/29/2014 | Q115 | ($0.33) | ($0.26) | $40.24 million | $41.40 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.28) | ($0.31) | $37.21 million | $39.56 million | View | Listen | |
| 4/30/2014 | Q114 | ($0.32) | ($0.32) | $34.15 million | $34.90 million | View | Listen | |
| 1/29/2014 | Q2 | ($0.34) | ($0.32) | $30.62 million | $32.30 million | View | Listen | |
| 8/7/2013 | Q4 2013 | ($0.30) | ($0.28) | $27.18 million | $28.80 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cardiovascular Systems (NASDAQ:CSII)2017 EPS Consensus Estimate: ($0.45)
2018 EPS Consensus Estimate: $0.11
2019 EPS Consensus Estimate: $0.23
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.44) | ($0.14) | ($0.26) |
| Q2 2017 | 4 | ($0.26) | ($0.05) | ($0.11) |
| Q3 2017 | 4 | ($0.05) | ($0.02) | ($0.04) |
| Q4 2017 | 4 | ($0.06) | ($0.02) | ($0.04) |
| Q1 2018 | 4 | ($0.08) | $0.00 | ($0.02) |
| Q2 2018 | 4 | ($0.01) | $0.03 | $0.02 |
| Q3 2018 | 3 | $0.04 | $0.05 | $0.04 |
| Q4 2018 | 4 | $0.05 | $0.09 | $0.08 |
| Q1 2019 | 1 | ($0.02) | ($0.02) | ($0.02) |
| Q2 2019 | 1 | $0.04 | $0.04 | $0.04 |
| Q3 2019 | 1 | $0.10 | $0.10 | $0.10 |
| Q4 2019 | 1 | $0.11 | $0.11 | $0.11 |
(Data provided by Zacks Investment Research)
Dividend History for Cardiovascular Systems (NASDAQ:CSII)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cardiovascular Systems (NASDAQ:CSII)Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 74.50%
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/31/2017 | Edward M Brown | Director | Sell | 20,000 | $29.16 | $583,200.00 | |
| 8/30/2017 | Edward M Brown | Director | Sell | 13,031 | $29.09 | $379,071.79 | |
| 8/17/2017 | Laura Gillund | Insider | Sell | 2,350 | $30.42 | $71,487.00 | |
| 8/17/2017 | Scott R Ward | CEO | Sell | 5,529 | $30.41 | $168,136.89 | |
| 8/16/2017 | Alexander Rosenstein | General Counsel | Sell | 979 | $30.71 | $30,065.09 | |
| 8/16/2017 | Kevin J Kenny | COO | Sell | 4,733 | $30.74 | $145,492.42 | |
| 8/16/2017 | Laurence L Betterley | CFO | Sell | 4,443 | $30.74 | $136,577.82 | |
| 5/17/2017 | Alexander Rosenstein | General Counsel | Sell | 219 | $32.30 | $7,073.70 | |
| 11/18/2016 | Alexander Rosenstein | General Counsel | Sell | 529 | $26.80 | $14,177.20 | |
| 11/18/2016 | Edward M Brown | Director | Sell | 10,000 | $26.78 | $267,800.00 | |
| 11/18/2016 | Laura Gillund | Insider | Sell | 1,268 | $26.79 | $33,969.72 | |
| 11/15/2016 | Edward M Brown | Director | Sell | 10,000 | $24.95 | $249,500.00 | |
| 10/10/2016 | Paul A Koehn | SVP | Sell | 30,910 | $25.07 | $774,913.70 | |
| 9/20/2016 | Camber Capital Management Llc | Major Shareholder | Sell | 1,100,000 | $23.26 | $25,586,000.00 | |
| 9/7/2016 | Paul A Koehn | SVP | Sell | 5,969 | $25.02 | $149,344.38 | |
| 8/22/2016 | Alexander Rosenstein | General Counsel | Sell | 234 | $23.82 | $5,573.88 | |
| 8/22/2016 | Kevin J Kenny | COO | Sell | 3,166 | $23.95 | $75,825.70 | |
| 8/22/2016 | Laura Gillund | Insider | Sell | 1,395 | $23.93 | $33,382.35 | |
| 8/22/2016 | Laurence L Betterley | CFO | Sell | 3,568 | $23.96 | $85,489.28 | |
| 8/22/2016 | Paul A Koehn | SVP | Sell | 2,527 | $23.92 | $60,445.84 | |
| 8/17/2016 | Paul A Koehn | SVP | Sell | 4,000 | $22.17 | $88,680.00 | |
| 2/26/2016 | Paul A Koehn | SVP | Sell | 956 | $38.79 | $37,083.24 | |
| 2/23/2016 | Camber Capital Management Llc | Major Shareholder | Buy | 250,000 | $7.55 | $1,887,500.00 | |
| 1/25/2016 | Scott R Ward | CEO | Buy | 2,700 | $9.30 | $25,110.00 | |
| 10/2/2015 | Robert J. Thatcher | insider | Sell | 64,700 | $16.31 | $1,055,257.00 | |
| 9/2/2015 | David Martin | CEO | Sell | 19,646 | $23.81 | $467,771.26 | |
| 9/1/2015 | Kevin J Kenny | COO | Sell | 5,289 | $23.85 | $126,142.65 | |
| 9/1/2015 | Laurence L Betterley | CFO | Sell | 9,597 | $23.96 | $229,944.12 | |
| 9/1/2015 | Paul A Koehn | SVP | Sell | 4,946 | $23.86 | $118,011.56 | |
| 9/1/2015 | Robert J Thatcher | Insider | Sell | 5,282 | $23.85 | $125,975.70 | |
| 8/18/2015 | David Martin | CEO | Sell | 17,688 | $23.99 | $424,335.12 | |
| 8/18/2015 | Kevin J. Kenny | COO | Sell | 3,913 | $24.00 | $93,912.00 | |
| 8/18/2015 | Laurence L Betterley | CFO | Sell | 8,476 | $24.00 | $203,424.00 | |
| 8/18/2015 | Paul A. Koehn | SVP | Sell | 4,402 | $23.99 | $105,603.98 | |
| 8/18/2015 | Robert J. Thatcher | insider | Sell | 2,960 | $23.99 | $71,010.40 | |
| 8/12/2015 | Brent G Blackey | Director | Buy | 2,500 | $22.74 | $56,850.00 | |
| 5/28/2015 | Paul A Koehn | SVP | Sell | 4,389 | $27.86 | $122,277.54 | |
| 5/1/2015 | Brent G Blackey | Director | Buy | 2,500 | $29.38 | $73,450.00 | |
| 2/10/2015 | David Martin | CEO | Sell | 7,500 | $35.85 | $268,875.00 | |
| 2/5/2015 | David Martin | CEO | Sell | 4,500 | $34.96 | $157,320.00 | |
| 1/29/2015 | Kevin J Kenny | VP | Sell | 4,212 | $35.00 | $147,420.00 | |
| 9/3/2014 | David Martin | CEO | Sell | 10,248 | $28.85 | $295,654.80 | |
| 9/3/2014 | Kevin J Kenny | VP | Sell | 3,528 | $28.85 | $101,782.80 | |
| 9/3/2014 | Laurence L Betterley | CFO | Sell | 4,674 | $28.82 | $134,704.68 | |
| 9/3/2014 | Paul A Koehn | SVP | Sell | 2,612 | $28.85 | $75,356.20 | |
| 9/3/2014 | Robert J Thatcher | Insider | Sell | 2,791 | $28.85 | $80,520.35 | |
| 8/28/2014 | Paul A Koehn | SVP | Sell | 1,315 | $28.82 | $37,898.30 | |
| 8/22/2014 | David Martin | CEO | Sell | 13,957 | $29.03 | $405,171.71 | |
| 8/22/2014 | Kevin J Kenny | VP | Sell | 2,914 | $29.09 | $84,768.26 | |
| 8/22/2014 | Laurence L Betterley | CFO | Sell | 6,578 | $29.02 | $190,893.56 | |
| 8/22/2014 | Paul A Koehn | SVP | Sell | 2,755 | $29.06 | $80,060.30 | |
| 8/22/2014 | Robert J Thatcher | Insider | Sell | 3,225 | $29.06 | $93,718.50 | |
| 8/19/2014 | David Martin | CEO | Sell | 11,754 | $29.28 | $344,157.12 | |
| 8/19/2014 | Kevin J Kenny | VP | Sell | 2,117 | $29.28 | $61,985.76 | |
| 8/19/2014 | Laurence L Betterley | CFO | Sell | 5,725 | $29.28 | $167,628.00 | |
| 8/19/2014 | Paul A Koehn | SVP | Sell | 2,168 | $29.28 | $63,479.04 | |
| 8/19/2014 | Robert J Thatcher | Insider | Sell | 2,537 | $29.28 | $74,283.36 | |
| 7/16/2014 | David Martin | CEO | Sell | 10,703 | $28.83 | $308,567.49 | |
| 7/16/2014 | Kevin J Kenny | VP | Sell | 3,007 | $28.83 | $86,691.81 | |
| 7/16/2014 | Laurence L Betterley | CFO | Sell | 3,984 | $28.83 | $114,858.72 | |
| 7/16/2014 | Paul A Koehn | SVP | Sell | 2,716 | $28.83 | $78,302.28 | |
| 7/16/2014 | Robert J Thatcher | Insider | Sell | 2,939 | $28.83 | $84,731.37 | |
| 4/25/2014 | Kevin Kenny | VP | Sell | 15,484 | $28.79 | $445,784.36 | |
| 2/24/2014 | David Martin | CEO | Sell | 29,200 | $37.31 | $1,089,452.00 | |
| 2/20/2014 | Kevin Kenny | VP | Sell | 6,779 | $36.02 | $244,179.58 | |
| 1/30/2014 | David Martin | CEO | Sell | 50,000 | $35.12 | $1,756,000.00 | |
| 1/30/2014 | Robert Thatcher | VP | Sell | 35,139 | $35.06 | $1,231,973.34 | |
| 11/22/2013 | Robert Thatcher | VP | Sell | 22,384 | $32.82 | $734,642.88 | |
| 10/31/2013 | James E Flaherty | Insider | Sell | 34,819 | $30.35 | $1,056,756.65 | |
| 10/23/2013 | David Martin | CEO | Sell | 154,080 | $27.73 | $4,272,638.40 | |
| 10/23/2013 | James E Flaherty | Insider | Sell | 36,682 | $26.85 | $984,911.70 | |
| 10/23/2013 | Robert J Thatcher | VP | Sell | 23,426 | $28.19 | $660,378.94 | |
| 10/22/2013 | Kevin J Kenny | VP | Sell | 5,608 | $27.31 | $153,154.48 | |
| 10/16/2013 | Kevin J Kenny | VP | Sell | 4,182 | $22.95 | $95,976.90 | |
| 10/14/2013 | David Martin | CEO | Sell | 21,170 | $22.00 | $465,740.00 | |
| 9/20/2013 | David Martin | CEO | Sell | 6,702 | $20.24 | $135,648.48 | |
| 9/20/2013 | James Flaherty | Insider | Sell | 2,066 | $20.28 | $41,898.48 | |
| 9/20/2013 | Robert Thatcher | VP | Sell | 1,274 | $20.28 | $25,836.72 | |
| 9/19/2013 | Laurence Betterley | CFO | Sell | 2,694 | $20.32 | $54,742.08 | |
| 9/19/2013 | Paul Koehn | SVP | Sell | 1,094 | $20.32 | $22,230.08 | |
| 9/18/2013 | David Martin | CEO | Sell | 8,030 | $20.94 | $168,148.20 | |
| 9/18/2013 | James Flaherty | Insider | Sell | 2,970 | $20.94 | $62,191.80 | |
| 9/18/2013 | Laurence Betterley | CFO | Sell | 4,324 | $20.93 | $90,501.32 | |
| 9/18/2013 | Paul Koehn | SVP | Sell | 1,732 | $20.93 | $36,250.76 | |
| 9/18/2013 | Robert Thatcher | VP | Sell | 1,731 | $20.94 | $36,247.14 | |
| 9/10/2013 | John Friedman | Director | Sell | 48,273 | $20.73 | $1,000,699.29 | |
| 8/30/2013 | David Martin | CEO | Sell | 21,552 | $20.64 | $444,833.28 | |
| 8/30/2013 | James Flaherty | Insider | Sell | 7,165 | $20.64 | $147,885.60 | |
| 8/30/2013 | Kevin Kenny | VP | Sell | 1,899 | $20.64 | $39,195.36 | |
| 8/30/2013 | Laurence Betterley | CFO | Sell | 8,692 | $20.64 | $179,402.88 | |
| 8/27/2013 | David Martin | CEO | Sell | 27,229 | $21.07 | $573,715.03 | |
| 8/27/2013 | James Flaherty | Insider | Sell | 9,051 | $21.07 | $190,704.57 | |
| 8/27/2013 | Kevin Kenny | VP | Sell | 2,396 | $21.07 | $50,483.72 | |
| 8/27/2013 | Laurence Betterley | CFO | Sell | 10,982 | $21.07 | $231,390.74 | |
| 8/16/2013 | James Flaherty | Insider | Sell | 1,255 | $20.51 | $25,740.05 | |
| 8/16/2013 | Laurence Betterley | CFO | Sell | 1,568 | $20.51 | $32,159.68 | |
| 8/14/2013 | James Flaherty | Insider | Sell | 4,902 | $21.31 | $104,461.62 | |
| 8/13/2013 | Kevin Kenny | VP | Sell | 2,529 | $21.20 | $53,614.80 | |
| 8/8/2013 | James Flaherty | Insider | Sell | 19,649 | $22.27 | $437,583.23 | |
| 7/30/2013 | David Martin | CEO | Sell | 11,094 | $19.69 | $218,440.86 | |
| 7/30/2013 | Laurence L Betterley | CFO | Sell | 6,579 | $19.72 | $129,737.88 | |
| 7/30/2013 | Robert J Thatcher | VP | Sell | 3,112 | $19.86 | $61,804.32 | |
| 6/3/2013 | James E Flaherty | Insider | Sell | 10,000 | $21.00 | $210,000.00 | |
| 5/31/2013 | Paul A Koehn | VP | Sell | 2,472 | $20.00 | $49,440.00 | |
| 5/28/2013 | Kevin J Kenny | VP | Sell | 4,182 | $19.95 | $83,430.90 | |
| 5/20/2013 | Glen D Nelson | Director | Buy | 10,250 | $18.47 | $189,317.50 | |
| 5/16/2013 | Glen D Nelson | Director | Buy | 4,753 | $18.93 | $89,974.29 | |
| 5/13/2013 | Glen D Nelson | Director | Buy | 18,393 | $18.11 | $333,097.23 | |
| 11/13/2012 | Glen D Nelson | Director | Buy | 33,000 | $11.96 | $394,680.00 | |
| 8/23/2012 | David Martin | CEO | Sell | 10,510 | $9.07 | $95,325.70 | |
| 8/23/2012 | James E Flaherty | Insider | Sell | 4,018 | $9.07 | $36,443.26 | |
| 8/23/2012 | Laurence L Betterley | CFO | Sell | 4,770 | $9.07 | $43,263.90 | |
| 8/23/2012 | Paul A Koehn | VP | Sell | 2,496 | $9.07 | $22,638.72 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cardiovascular Systems (NASDAQ:CSII)
Latest Headlines for Cardiovascular Systems (NASDAQ:CSII)
| Source: |
|
| Date | Headline |
|---|
 | Head-To-Head Survey: Cardiovascular Systems (CSII) vs. Its Competitors
www.americanbankingnews.com - October 20 at 12:32 AM |
| Cardiovascular Systems (CSII) and VWR Corporation (VWR) Head-To-Head Comparison
www.americanbankingnews.com - October 18 at 2:24 PM |
 | ETFs with exposure to Cardiovascular Systems, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 6:20 PM |
| Cardiovascular Systems, Inc. (CSII) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 17 at 5:20 AM |
 | Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular ... - PR Newswire (press release)
www.prnewswire.com - October 13 at 4:22 AM |
| Needham & Company LLC Reiterates "Buy" Rating for Cardiovascular Systems, Inc. (CSII)
www.americanbankingnews.com - October 12 at 11:38 AM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cardiovascular Systems, Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - October 11 at 7:06 PM |
| -$0.07 Earnings Per Share Expected for Cardiovascular Systems, Inc. (CSII) This Quarter
www.americanbankingnews.com - October 11 at 4:30 AM |
| Cardiovascular Systems, Inc. (CSII) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 10 at 10:46 PM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cardiovascular Systems, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - October 9 at 3:53 PM |
| Financial Analysis: Cardiovascular Systems (CSII) versus The Competition
www.americanbankingnews.com - October 7 at 8:24 PM |
| ETFs with exposure to Cardiovascular Systems, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 5:48 PM |
| Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: Q4, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 10:50 AM |
 | Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular ... - Business Wire (press release)
www.businesswire.com - October 4 at 4:16 PM |
| Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular Systems, Inc. (CSII)
finance.yahoo.com - October 4 at 4:16 PM |
 | Scott Ward receives more than $5.2M in first full year as CEO of Cardiovascular Systems Inc.
www.bizjournals.com - October 4 at 11:34 AM |
| Cardiovascular Systems to Webcast Fiscal 2018 First-Quarter Earnings Conference Call Wednesday, October 25
finance.yahoo.com - October 4 at 11:34 AM |
| Reviewing Intersect ENT (XENT) and Cardiovascular Systems (CSII)
www.americanbankingnews.com - September 27 at 10:36 AM |
| Cardiovascular Systems, Inc. (CSII) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 27 at 4:42 AM |
| Cardiovascular Systems, Inc. (CSII) Receives New Coverage from Analysts at Raymond James Financial, Inc.
www.americanbankingnews.com - September 22 at 9:18 AM |
| Cardiovascular Systems, Inc. (CSII) Earns Market Perform Rating from Analysts at Citigroup Inc.
www.americanbankingnews.com - September 21 at 5:38 PM |
| Leerink Swann Equities Analysts Lower Earnings Estimates for Cardiovascular Systems, Inc. (CSII)
www.americanbankingnews.com - September 20 at 9:22 AM |
 | Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance? - Nasdaq
www.nasdaq.com - September 19 at 5:35 PM |
| Cardiovascular Systems, Inc. (CSII) Forecasted to Post Q2 2018 Earnings of ($0.01) Per Share
www.americanbankingnews.com - September 19 at 9:24 AM |
| Cardiovascular Systems Announces Anticipated Revenue Impact ... - Business Wire (press release)
www.businesswire.com - September 18 at 10:36 PM |
| Cardiovascular Systems suffers a hurricane hangover
www.bizjournals.com - September 18 at 5:34 PM |
 | CSII Crosses Below Key Moving Average Level
www.thestreet.com - September 18 at 5:34 PM |
| Commit To Purchase Cardiovascular Systems At $25, Earn 10.4% Annualized Using Options
www.nasdaq.com - September 14 at 6:25 PM |
 | Cardiovascular Systems (CSII) Presents At Lake Street Capital Best Ideas Growth Conference - Slideshow
seekingalpha.com - September 14 at 6:25 PM |
| Cardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - September 9 at 5:14 PM |
| Cardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 8 at 5:59 PM |
| Cardiovascular Systems (CSII) Catches Eye: Stock Jumps 6.9%
finance.yahoo.com - September 5 at 7:10 PM |
| Cardiovascular Systems, Inc. breached its 50 day moving average in a Bullish Manner : CSII-US : September 5, 2017
finance.yahoo.com - September 5 at 7:10 PM |
| $53.41 Million in Sales Expected for Cardiovascular Systems, Inc. (CSII) This Quarter
www.americanbankingnews.com - September 5 at 1:56 AM |
| Cardiovascular Systems, Inc. (CSII) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 2 at 4:40 AM |
| Edward M. Brown Sells 13,031 Shares of Cardiovascular Systems, Inc. (CSII) Stock
www.americanbankingnews.com - September 1 at 7:42 PM |
| Edward M. Brown Sells 20,000 Shares of Cardiovascular Systems, Inc. (CSII) Stock
www.americanbankingnews.com - September 1 at 7:40 PM |
| ETFs with exposure to Cardiovascular Systems, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:32 PM |
| Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: 2017 By the Numbers : August 28, 2017
finance.yahoo.com - August 28 at 5:24 PM |
| Notable Two Hundred Day Moving Average Cross - CSII
www.nasdaq.com - August 25 at 9:43 PM |
| Cardiovascular Systems (CSII) Presents At CFA Society Of Minnesota 6th Annual Intellisight Conference - Slideshow
seekingalpha.com - August 23 at 7:11 PM |
| Haeggquist & Eck Investigates Cardiovascular Systems Inc. for ... - Business Wire (press release)
www.businesswire.com - August 22 at 11:11 PM |
| Haeggquist & Eck Investigates Cardiovascular Systems Inc. for Paying Illegal Kickbacks, Promoting Its Devices for Off-Label Purposes, and Violating FDA Laws and Regulations
finance.yahoo.com - August 22 at 11:11 PM |
| Cardiovascular Systems, Inc. (CSII) Insider Laura Gillund Sells 2,350 Shares
www.americanbankingnews.com - August 21 at 8:10 PM |
| Cardiovascular Systems, Inc. (CSII) CEO Sells $168,136.89 in Stock
www.americanbankingnews.com - August 21 at 7:46 PM |
| Cardiovascular Systems, Inc. (CSII) Expected to Post Quarterly Sales of $53.41 Million
www.americanbankingnews.com - August 18 at 3:30 PM |
| Insider Selling: Cardiovascular Systems, Inc. (CSII) General Counsel Sells 979 Shares of Stock
www.americanbankingnews.com - August 17 at 8:52 PM |
| Insider Selling: Cardiovascular Systems, Inc. (CSII) CFO Sells 4,443 Shares of Stock
www.americanbankingnews.com - August 17 at 8:32 PM |
| Insider Selling: Cardiovascular Systems, Inc. (CSII) COO Sells 4,733 Shares of Stock
www.americanbankingnews.com - August 17 at 8:32 PM |
| Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
finance.yahoo.com - August 15 at 6:18 PM |
Cardiovascular Systems (CSII) Chart for Saturday, October, 21, 2017
